Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 18/20 | 0.59 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | MARK3 | P27448 | 2/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.44 |
| ▸ | BRSK2 | Q8IWQ3 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284874 | 0.91 | TBK1 (0.67) | TBK1MARK3IKBKEULK1ULK2 | |
| SCHEMBL15163314 | 0.89 | TBK1 (0.46) | TBK1SYK | |
| SCHEMBL1284924 | 0.82 | TBK1 (0.68) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL1284415 | 0.82 | TBK1 (0.65) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL1284538 | 0.82 | TBK1 (0.71) | TBK1SYKCDK2MARK3IKBKE | |
| SCHEMBL1284522 | 0.81 | TBK1 (0.68) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL1285127 | 0.81 | TBK1 (0.67) | TBK1SYKCDK2MARK3IKBKE | |
| SCHEMBL1284504 | 0.81 | TBK1 (0.66) | TBK1CDK2MARK3IKBKEBRSK2 | |
| SCHEMBL3719363 | 0.81 | SYK (0.43) | SYKCDK2MARK3AURKB | |
| SCHEMBL1284279 | 0.80 | TBK1 (0.70) | TBK1CDK2MARK3IKBKEBRSK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268897-A1 | Phosphatase Binding Compounds and Methods of Using Same | YALE UNIVERSITY | 2020-08-27 | — | — | US | disclosed |
| EP-2403853-B1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | TBK1 17/4885SYK 230/4885CDK2 89/4885 |
| US-20200268897-A1 | Phosphatase Binding Compounds and Methods of Using Same | PPP5C, PPP4C, DUSP26 | TBK1 1037/4885SYK 2800/4885CDK2 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.